yttrium-90 citrate colloid

Yttrium-90 citrate colloid is a radiopharmaceutical used primarily for radiosynovectomy—the local treatment of joint disorders characterized by synovial hypertrophy and chronic inflammation, such as rheumatoid arthritis. It consists of the radioisotope yttrium‑90 complexed with citric acid to form a stable colloidal suspension. When injected intra-articularly, the beta radiation emitted by Yttrium‑90 ablates hyperplastic synovial tissue while minimizing exposure to surrounding structures due to its short penetration range. This targeted approach reduces inflammation and improves joint function in affected patients[4][5][7]. The preparation is typically achieved using a specific ratio of carrier yttrium and citrate to ensure optimal localization within the synovial membrane[5].

Other names

1,2,3-propanetricarboxylic acid, 2-hydroxy-, yttrium(3+)-90Y salt (1:1)UNII-J8L3BWC4BDUNII-J-8L3BWC4BDUNII-J 8L3BWC4BDEINECS 266-546-9EINECS266-546-9EINECS-266-546-9